Table 2.
Kinase inhibitor sensitivity
| A204 | RD18 | MNNG | U2OS | Saos2 | MG63 | A673 | RD-ES | SK-LMS1 | HT1080 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Erlotinib | >10 | >10 | >10 | >10 | >10 | >10 | >10 | >10 | >10 | 9.63 |
| Dasatinib | 0.03 | 6.07 | >10 | >10 | 0.39 | 0.80 | 6.75 | >10 | >10 | 1.62 |
| Imatinib | 0.13 | >10 | >10 | >10 | >10 | >10 | >10 | >10 | >10 | >10 |
| PHA665752 | 4.20 | 2.87 | 0.33 | 8.03 | 3.03 | 2.50 | 3.33 | 6.31 | >10 | 3.10 |
| OSI868 | 9.80 | >10 | >10 | >10 | 2.24 | 4.83 | 4.26 | 0.10 | >10 | 4.12 |
| SU5402 | 15.24 | >40 | >40 | >40 | >40 | 34.08 | >40 | >40 | >40 | >40 |
| JAK | 9.23 | >10 | 3.47 | >10 | >10 | >10 | >10 | 8.36 | >10 | 0.91 |
| ZD6474 | 5.77 | 9.33 | 6.37 | >10 | >10 | 8.28 | 5.37 | 5.78 | >10 | 9.04 |
NOTE: IC50 values for each indicated compound tested in the 10 sarcoma cell lines. Values are given in μmol/L.